Elsbet Pieterman
Overview
Explore the profile of Elsbet Pieterman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
253
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carracedo M, Pawelzik S, Artiach G, Pouwer M, Plunde O, Saliba-Gustafsson P, et al.
Br J Pharmacol
. 2022 Jun;
179(19):4709-4721.
PMID: 35751904
Background And Purpose: Tyrosine kinase inhibitors (TKI) used to treat chronic myeloid leukaemia (CML) have been associated with cardiovascular side effects, including reports of calcific aortic valve stenosis. The aim...
2.
Morrison M, Verschuren L, Salic K, Verheij J, Menke A, Wielinga P, et al.
Hepatol Commun
. 2018 Dec;
2(12):1513-1532.
PMID: 30556039
Concerns have been raised about whether preclinical models sufficiently mimic molecular disease processes observed in nonalcoholic steatohepatitis (NASH) patients, bringing into question their translational value in studies of therapeutic interventions...
3.
Morrison M, Liang W, Mulder P, Verschuren L, Pieterman E, Toet K, et al.
J Hepatol
. 2014 Dec;
62(5):1180-6.
PMID: 25514555
Background & Aims: Anthocyanins may have beneficial effects on lipid metabolism and inflammation and are demonstrated to have hepatoprotective properties in models of restraint-stress- and chemically-induced liver damage. However, their...
4.
Kuhnast S, van der Tuin S, van der Hoorn J, van Klinken J, Simic B, Pieterman E, et al.
Eur Heart J
. 2014 Aug;
36(1):39-48.
PMID: 25142968
Background: The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as...
5.
de Poorter J, Tolboom T, Rabelink M, Pieterman E, Hoeben R, Nelissen R, et al.
J Gene Med
. 2005 Jun;
7(11):1421-8.
PMID: 15977303
Background: Loosening is a major complication in prosthesis surgery. To stabilize loosened orthopedic implants, the interface tissue surrounding the implant must be removed. As an alternative to manual removal, we...
6.
Kasperkovitz P, Timmer T, Smeets T, Verbeet N, Tak P, van Baarsen L, et al.
Arthritis Rheum
. 2005 Feb;
52(2):430-41.
PMID: 15692990
Objective: Given the heterogeneity of gene expression patterns and cellular distribution between rheumatoid arthritis (RA) synovial tissues, we sought to determine whether this variability was also reflected at the level...
7.
van der Pouw Kraan T, van Gaalen F, Kasperkovitz P, Verbeet N, Smeets T, Kraan M, et al.
Arthritis Rheum
. 2003 Aug;
48(8):2132-45.
PMID: 12905466
Objective: To generate a molecular description of synovial tissue from rheumatoid arthritis (RA) patients that would allow us to unravel novel aspects of pathogenesis and to identify different forms of...
8.
Tolboom T, Medema J, van Gaalen F, Pieterman E, Huizinga T, Toes R
Arthritis Rheum
. 2003 Mar;
48(3):858-9; author reply 859.
PMID: 12632447
No abstract available.